Abstract 397P
Background
OBI-833 is a novel cancer vaccine targeting a tumor-associated carbohydrate antigen, Globo H. Results of the dose-escalation trial, which showed a favorable safety profile, supported the following cohort expansion trial in non-small cell lung cancer (NSCLC) patients at a dose of 30 μg.
Methods
Patients with Globo H-positive metastatic NSCLC who have achieved stable disease (SD), or partial response (PR) after at least one regimen of anticancer therapy were enrolled. For patients who were on the targeted therapy, OBI-833 was added to their ongoing therapies. Humoral immune responses and relevant tumor biomarkers were monitored.
Results
A total of 14 patients were successfully enrolled. Treatment is ongoing for five patients. Nine patients have been discontinued. Eleven patients were treated with a 1st or 2nd-generation EGFR TKI and OBI-833, one patient with ceritinib plus OBI-833, and two patients with OBI-833 monotherapy. As of June 2020, a total of 79 treatment-related AEs were reported. Most were injection site reactions. Among the 6 reported SAEs, one was treatment-related, which was Grade 4 acute pancreatitis, and five were non-treatment related. The Globo H expression of the tumor specimens was evaluated by IHC and reported as H score. At the H score cutoffs of 0 and 100, 71% (17/24) and 50% (12/24) of the screened patients were Globo H positive, respectively. Thirteen (93%) and nine (64%) patients showed blood levels of anti-Globo H IgM and IgG. The positivity was defined as the anti-Globo H IgM or IgG concentration ≥ 3 μg/mL at least once during the study period. Median PFS was 31 weeks (range, 3–108). Six of the 11 EGFR TKI-treated patients had SD for over six months. One patient has been treated for more than two years and his treatment is still ongoing. Of note, one patient’s tumor size had reduced by 27% after 16 months of OBI-833 treatment. Plasma EGFR mutation load was significantly reduced from 8.57 to 0 in another patient.
Conclusions
OBI-833 can elicit a beneficial immune response in NSCLC patients and had rendered some TKI-treated patients durable stable disease status. Further development of OBI-833 in EGFR-mutated NSCLC patients to assess the potential benefits of combination therapy of OBI-833 with TKIs is ongoing.
Clinical trial identification
NCT02310464.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
OBI Pharma.
Disclosure
C-C. Ou, C-E. Tsai: Full/Part-time employment: OBI Pharma. P-C. Yang: Advisory/Consultancy: OBI Pharma. All other authors have declared no conflicts of interest.
Resources from the same session
94P - Prognostic influence of mean platelet volume on stage III rectal cancer patients: A tertiary cancer center study
Presenter: Pavan Jonnada
Session: e-Poster Display Session
95P - Prognosis of Japanese patients with detailed RAS/BRAF mutant colorectal cancer
Presenter: Tatsuki Ikoma
Session: e-Poster Display Session
96P - Early-onset colorectal cancer prognosis, conflict resolution, review of literature and meta-analysis
Presenter: Ereny Poles
Session: e-Poster Display Session
97P - A population-based study to assess the associations of rural residence and low socioeconomic status (SES) with cardiovascular disease (CVD) in patients with colorectal cancer (CRC)
Presenter: Atul Batra
Session: e-Poster Display Session
98P - Operational challenges of an Asian Pacific (APAC) academic oncology clinical trial
Presenter: Daphne Day
Session: e-Poster Display Session
99P - Development of a qRT-PCR-based diagnostic test to identify colorectal cancer patients with recurrent R-Spondin gene fusions
Presenter: Veronica Diermayr
Session: e-Poster Display Session
100P - Individualized treatment of advanced digestive system tumour guided by PDTX mouse model: A multicenter trial
Presenter: yuan cheng
Session: e-Poster Display Session
101P - HIF1-α depletion overcomes resistance to oxaliplatin in colorectal cancer via ERK signalling pathway
Presenter: Se Jun Park
Session: e-Poster Display Session
102P - Colorectal cancer organoids culture exploits new neoadjuvant therapy resistance mechanisms and therapeutic targets
Presenter: Yun Deng
Session: e-Poster Display Session
103P - Comprehensive genomic landscape in younger and older Chinese patients with colorectal cancer
Presenter: Huina Wang
Session: e-Poster Display Session